#None #Madrid #TKI #OncoHost #ESMO 2026

OncoHost Unveils Groundbreaking Research on TKI Sensitivity

OncoHost, a pioneering technology company focusing on precision diagnostics, presented its latest findings at the European Society for Medical Oncology (ESMO) 2026 Congress in Madrid, Spain, held from October 23 to 27. The research highlights the biological mechanisms behind sensitivity to tyrosine kinase inhibitors (TKIs) in patients with metastatic renal cell carcinoma (mRCC).

The study titled "Plasma Proteomics Reveals the Biological Landscape of Tyrosine Kinase Inhibitors (TKI) Sensitivity in Metastatic Renal Cell Carcinoma" introduces a model based on pre-treatment plasma proteomics to classify mRCC patients as either TKI-Positive or TKI-Negative. This classification provides valuable insights into which patients are more likely to benefit from first-line treatment with combined immune checkpoint inhibitors (ICI) and TKIs versus dual immunotherapy.

Unveiling New Layers of TKI Sensitivity

The challenge of selecting appropriate treatment strategies for mRCC remains significant for clinicians. With various effective approaches available—including dual immunotherapy and ICI-TKI combinations—doctors often face the dilemma of insufficient biomarker guidance to determine the most beneficial course for patients. OncoHost’s innovative blood-based model offers a solution by helping identify candidates who would respond favorably to TKI-centric therapies.

Developed in collaboration with Dana-Farber Cancer Institute, this model employs an analysis of plasma proteins collected before the commencement of treatment. Recent findings presented at ESMO connect the predictive model's proteins to various biological processes, such as angiogenesis and inflammation, thus illuminating the complexities tied to TKI sensitivity and inherent resistance.

Dr. Wenxin Xu, an oncologist and principal investigator from Dana-Farber Cancer Institute, noted, "We previously identified a plasma proteomic score that correlates with improved outcomes following VEGFR TKI treatment for RCC. Our current examination digs deeper into the biological basis of this score, illustrating that pathways related to vascular remodeling and inflammation are fundamental to TKI sensitivity in RCC."

Key Insights from the Research

The model has shown promising potential, having been initially developed on 119 patients and validated in another 59. Results indicate that patients identified as TKI-Positive demonstrated significantly increased overall survival rates when treated with ICI-TKI combinations, compared to those receiving dual immunotherapy. The study at ESMO also investigated whether the proteins identified in the model align with biological processes relevant to TKI efficacy and resistance.

Major Findings:

• - Strong Angiogenic Signature: Among the 169 core predictive proteins, 82 were tied to angiogenesis and vascular remodeling, notably influencing the VEGF signaling pathway.
• - Complex Pathways: Additional proteins were linked to VEGF-independent angiogenesis, inflammation, and tumor plasticity, underscoring the intricate nature of TKI sensitivity.
• - Tumor Microenvironment Analysis: Insights from protein origin analyses suggested that the proteomic signatures constitute contributions from tumor cells, immune cells, and the surrounding stromal environment.

The overlap of model proteins with established angiogenic molecular programs in RCC lends biological validity to the association with TKI outcomes. These findings propose a multifaceted understanding of treatment sensitivity and resistance, moving beyond simplistic interpretations associated with singular angiogenic pathways.

As Dr. Ofer Sharon, CEO of OncoHost, articulated, "The synergistic alignment of mathematical, biological, and clinical signals in our findings is compelling. The proteins selected were initially chosen for their predictive capabilities regarding ICI-TKI outcomes, and the recurring themes of vascular remodeling and angiogenesis we observed suggest that our model captures meaningful biological pathways rather than mere statistical correlations."

The Future of OncoHost

Headquartered in Binyamina, Israel, and Cary, North Carolina, OncoHost continues to revolutionize precision medicine with its innovative platform, PROphet®. This plasma-based proteomic analysis tool is designed to guide clinical decisions in oncology, starting with non-small cell lung cancer (NSCLC). By leveraging a single blood sample to optimize treatment strategies, OncoHost aims to improve patient outcomes significantly.

The commitment and expertise of OncoHost’s team, bolstered by an extensive prospective clinical trial involving over 1,700 patients across more than 40 sites globally, position the company as a leader in the field of precision diagnostics and biomarker development.

For more information, feel free to visit OncoHost’s website or follow them on LinkedIn, Twitter, Facebook, and YouTube.